|
Mavoglurant
|
DB13004 |
[Mavoglurant has been used in trials studying the treatment of Patient Diagnosed With OCD and and Resistant to SSRI Treatment (Failed SSRI Over 12 Weeks at Appropriate Doses).] |
|
Angelica sinensis root
|
DB14336 |
[Angelica sinensis root is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.] |
|
Bergamot oil
|
DB14335 |
[Bergamot oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.] |
|
Rebastinib
|
DB13005 |
[Rebastinib has been used in trials studying the treatment of Chronic Myeloid Leukemia.] |
|
Atractylodes lancea root oil
|
DB14338 |
[Atractylodes lancea root oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.] |
|
Cibinetide
|
DB13006 |
[Cibinetide has been used in trials studying the basic science of Depression.] |
|
Enfortumab vedotin
|
DB13007 |
[Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers.[L10836] It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable link.[L10836] It is similar to [brentuximab vedotin], another antibody conjugated with MMAE that targets CD-30 instead of Nectin-4.
The clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics[A188868] and it was first approved for use in the United States in December 2019 under the brand name Padcev<sup>TM</sup>.[L10836]] |
|
Salvia miltiorrhiza root
|
DB14337 |
[Salvia miltiorrhiza root is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.] |
|
PCI-27483
|
DB13000 |
[PCI-27483 has been used in trials studying the treatment of Pancreatic Cancer, Ductal Adrenocarcinoma, and Exocrine Pancreatic Cancer.] |
|
Inonotus obliquus fruiting body
|
DB14332 |
[Inonotus obliquus fruiting body is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.] |
|
Heterotheca inuloides flower
|
DB14331 |
[Heterotheca inuloides flower is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.] |
|
Tinoridine
|
DB13001 |
[Tinoridine is under investigation in clinical trial NCT01224756 (Efficacy of Tinoridine in Treating Pain and Inflammation in Adults).] |
|
Hydrogenated coconut oil
|
DB14334 |
[Hydrogenated coconut oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.] |
|
HKI-357
|
DB13002 |
[Hki 357 is under investigation in clinical trial NCT00550381 (Study Evaluating the Safety, Tolerability, and Pharmacokinetics (PK) of HKI-357 Administered Orally to Healthy Subjects).] |
|
Cortivazol
|
DB13003 |
[Cortivazol is under investigation in clinical trial NCT00804895 (Cluster Headache Cortivazol Injection (CHCI)).] |
|
Nelumbo nucifera flower
|
DB14333 |
[Nelumbo nucifera flower is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.] |
|
Macadamia oil
|
DB14330 |
[Macadamia oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.] |
|
Irbesartan
|
DB01029 |
[Irbesartan is an angiotensin receptor blocker (ARB) indicated to treat hypertension or diabetic nephropathy.[L7456,L7459] It can also be used as part of a combination product with [hydrochlorothiazide] for patients not well controlled or not expected to be well controlled on monotherapy.[L7459] Unlike angiotensin converting enzyme inhibitors, ARBs are not associated with a dry cough.[L7456,L7459]
Irbesartan was granted FDA approval on 30 September 1997.[L7456,L7459]] |
|
LY374571
|
DB02358 |
|
|
Ketoconazole
|
DB01026 |
[Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.[FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.[A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981.[A188054] At this time it was considered a significant improvement over previous antifungals, [miconazole] and [clotrimazole], due to its broad spectrum and good absorption. However, it was discovered that ketoconazole produces frequent gastrointestinal side effects and dose-related hepatitis.[A188054,A188057] These effects combined with waning efficacy led to its eventual replacement by triazole agents, [fluconazole], [itraconazole], [voraconazole], and [posaconazole]. Ketoconazole and its predecessor [clotrimazole] continue to be used in topical formulations.] |
